CANTOS: A randomized, double blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
PHASE: Follow Up (no longer accepting new patients)
PRINCIPAL INVESTIGATOR: Karen Sopko, MD, FACC
Mark Bieniarz, MD, FACC, FSCAI
Brendan Cavanaugh, MD, FACC
Mihaela Bujoi, MD, FACC